000 | 01866nim a2200457 a 4500 | ||
---|---|---|---|
001 | HST8225 | ||
003 | UkLoHST | ||
006 | m o h | ||
007 | cr nna|||||||| | ||
007 | sr |mnnnnnzne| | ||
008 | 210504s2021 enk|||||o||h||||||||eng d | ||
028 | 5 | 0 |
_a8225 _bHenry Stewart Talks |
035 | _a(UkLoHST)4638 | ||
040 |
_aUkLoHST _beng _cUkLoHST |
||
100 | 1 |
_aMüller, Christa E., _u(University of Bonn, Germany) _4spk |
|
245 | 1 | 0 |
_aIdentifying SARS-CoV-2 proteases _h[electronic resource] / _can interview with Christa E. Müller and Michael Gütschow. |
260 |
_aLondon : _bHenry Stewart Talks, _c2021. |
||
300 | _a1 online resource (1 streaming audio file (10 min.)). | ||
490 | 1 |
_aInterviews on Covid-19, _x2056-452X |
|
500 | _aAudio interview. | ||
500 | _aTitle from title frames. | ||
505 | 0 | _aContents: The two SARS-CoV-2 proteases found and their mechanisms of action -- Designing inhibitors to these proteases -- Steps taken in this research -- Future work. | |
506 | _aAccess restricted to subscribers. | ||
538 | _aMode of access: World Wide Web. | ||
650 | 0 | _aCoronaviruses. | |
650 | 0 |
_aCOVID-19 (Disease) _xResearch. |
|
650 | 0 | _aDrug development. | |
650 | 0 | _aProtease inhibitors. | |
650 | 0 | _aProteolytic enzymes. | |
650 | 2 |
_aCOVID-19 _xdrug therapy. |
|
650 | 2 |
_aDrug Development _xmethods. |
|
650 | 2 |
_aPeptide Hydrolases _xisolation & purification. |
|
650 | 2 |
_aProtease Inhibitors _xpharmacology. |
|
650 | 2 | _aSARS-CoV-2. | |
650 | 2 |
_aVirus Internalization _xdrug effects. |
|
650 | 2 |
_aVirus Replication _xdrug effects. |
|
700 | 1 |
_aGütschow, Michael _u(University of Bonn, Germany) _4spk |
|
830 | 0 |
_aHenry Stewart talks. _pBiomedical & life sciences collection. _pInterviews on Covid-19. |
|
856 | 4 | 0 | _uhttps://hstalks.com/bs/4638/ |
856 | 4 | 2 |
_uhttps://hstalks.com/bs/p/1060/ _3Series |
999 |
_c75778 _d75778 |